HomeBUSINESS
BUSINESS

Ono Lifts Half-Year Guidance on Opdivo Boon
(Oct.27.2017)

Ono Pharmaceutical said on October 26 that it has raised its April-September earnings estimate thanks to better-than-expected Opdivo (nivolumab) sales and royalties, and a rollover of part of R&D and SGA costs to the third quarter ...
(LOG IN FOR FULL STORY)

News Calendar